2012 ASCO Annual Meeting Sunday

Chicago, IL - ASCO 2012 Annual Meeting: - Kimberly L. Blackwell, MD presents Abstract #LBA1 View Abstract: Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane.
Kimberly L. Blackwell, MD
1:45 PM - 2:00 PM
Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane.
Kimberly L. Blackwell, MD during the American Society for Clinical Oncology (ASCO) Annual Meeting here today, Sunday June 3, 2012. Over 31,000 physicians, researchers and healthcare professionals from over 100 countries are attending the meeting which is being held at the McCormick Convention center and features the latest cancer research in the areas of basic and clinical science. Photo by © ASCO/Todd Buchanan 2012 Technical Questions: todd@toddbuchanan.com; ASCO Contact: photos@asco.org